Share information
204.60 €
-0.68 %
16/10/2026 17:37
-0.68 %
Open
High
Low
Volume
204.50 €
205.10 €
201.30 €
324,449
Latest News
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
30-Sep-2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa
29-Sep-2026
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
09-Sep-2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA[®] (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)